Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Lisata Therapeutics (LSTA) over the last 8 years, with Q1 2017 value amounting to $5.4 million.

  • Lisata Therapeutics' Current Deferred Revenue fell 485.91% to $5.4 million in Q1 2017 from the same period last year, while for Mar 2017 it was $5.4 million, marking a year-over-year decrease of 485.91%. This contributed to the annual value of $5.1 million for FY2016, which is 462.15% down from last year.
  • Latest data reveals that Lisata Therapeutics reported Current Deferred Revenue of $5.4 million as of Q1 2017, which was down 485.91% from $5.1 million recorded in Q4 2016.
  • In the past 5 years, Lisata Therapeutics' Current Deferred Revenue registered a high of $7.2 million during Q2 2016, and its lowest value of $362041.0 during Q2 2013.
  • In the last 5 years, Lisata Therapeutics' Current Deferred Revenue had a median value of $4.6 million in 2015 and averaged $4.0 million.
  • In the last 5 years, Lisata Therapeutics' Current Deferred Revenue plummeted by 7780.9% in 2013 and then soared by 68183.02% in 2014.
  • Over the past 5 years, Lisata Therapeutics' Current Deferred Revenue (Quarter) stood at $1.8 million in 2013, then surged by 138.58% to $4.3 million in 2014, then grew by 23.33% to $5.3 million in 2015, then decreased by 4.62% to $5.1 million in 2016, then grew by 5.23% to $5.4 million in 2017.
  • Its Current Deferred Revenue stands at $5.4 million for Q1 2017, versus $5.1 million for Q4 2016 and $5.9 million for Q3 2016.